Amgen (NAS:AMGN) Accounts Payable

: $1,320 Mil (As of Mar. 2023)

View and export this data going back to 1983. Start your Free Trial

Amgen's Accounts Payable for the quarter that ended in Mar. 2023 was $1,320 Mil.

Amgen's quarterly Accounts Payable increased from Sep. 2022 ($1,204 Mil) to Dec. 2022 ($1,572 Mil) but then declined from Dec. 2022 ($1,572 Mil) to Mar. 2023 ($1,320 Mil).

Amgen's annual Accounts Payable declined from Dec. 2020 ($1,421 Mil) to Dec. 2021 ($1,366 Mil) but then increased from Dec. 2021 ($1,366 Mil) to Dec. 2022 ($1,572 Mil).

Amgen Accounts Payable Historical Data

The historical data trend for Amgen's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable

1,207.00

1,371.00

1,421.00

1,366.00

1,572.00

Amgen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Accounts Payable																1,403.00	1,256.00	1,204.00	1,572.00	1,320.00

Amgen Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Amgen Accounts Payable Related Terms

Thank you for viewing the detailed overview of Amgen's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (NAS:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (NAS:AMGN) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

AMG N:Mexico 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Executives

Michael V Drake	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller	officer: SVP, Human Resources	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Rachna Khosla	officer: SVP, Business Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Amy E Miles	director
Linda H. Louie	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Nancy A. Grygiel	officer: SVP & CCO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Peter H. Griffith	officer: EVP & CFO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon	officer: EVP Global Commercial Ops	C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
David M Reese	officer: EVP, Research and Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Brian Druker	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Wanda M Austin	director	6001 BOLLINGER CANYON ROAD, SAN RAMON CA 94583
Charles M Holley	director
Lori A Johnston	officer: SVP, HR	C/O AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Ellen Jamison Kullman	director	UNITED TECHNOLOGIES CORP, 10 FARM SPRINGS ROAD, FARMINGTON CT 06032